US 12,071,670 B2
Method for determining in vitro or ex vivo the immune status of an individual
Marine Mommert, Lyons (FR); Olivier Tabone, Lyons (FR); Julien Textoris, Villeurbanne (FR); and François Mallet, Villeurbanne (FR)
Assigned to BIOMÉRIEUX, Marcy l'Etoile (FR)
Appl. No. 17/256,811
Filed by BIOMÉRIEUX, Marcy l'Etoile (FR)
PCT Filed Jun. 28, 2019, PCT No. PCT/EP2019/067330
§ 371(c)(1), (2) Date Dec. 29, 2020,
PCT Pub. No. WO2020/002602, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 18180991 (EP), filed on Jun. 29, 2018; and application No. 18/58167 (FR), filed on Sep. 12, 2018.
Prior Publication US 2021/0254165 A1, Aug. 19, 2021
Int. Cl. C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/158 (2013.01)] 15 Claims
 
1. A method of detecting and/or quantifying expression of Human Endogenous RetroViruses/Mammalian apparent LTR-Retrotransposons (HERV/MaLR) sequences comprising:
obtaining a blood sample collected from an individual with sepsis; and
assaying the blood sample to detect and/or quantify expression of a combination of at least two HERV/MaLR sequences,
wherein the combination includes HERV/MaLR sequences having at least 99% identity with each of SEQ ID NOS: 1, 3, 8, 11, 12, 13, and 28.